112.77
price down icon0.19%   -0.22
pre-market  Vorhandelsmarkt:  112.94   0.17   +0.15%
loading
Schlusskurs vom Vortag:
$112.99
Offen:
$113.15
24-Stunden-Volumen:
3.93M
Relative Volume:
0.59
Marktkapitalisierung:
$139.93B
Einnahmen:
$28.80B
Nettoeinkommen (Verlust:
$6.31B
KGV:
22.46
EPS:
5.02
Netto-Cashflow:
$9.37B
1W Leistung:
+0.19%
1M Leistung:
-1.52%
6M Leistung:
-1.72%
1J Leistung:
+42.51%
1-Tages-Spanne:
Value
$112.28
$113.83
1-Wochen-Bereich:
Value
$111.28
$113.83
52-Wochen-Spanne:
Value
$77.74
$121.83

Gilead Sciences Inc Stock (GILD) Company Profile

Name
Firmenname
Gilead Sciences Inc
Name
Telefon
(650) 574-3000
Name
Adresse
333 LAKESIDE DR, FOSTER CITY, CA
Name
Mitarbeiter
17,600
Name
Twitter
@GileadSciences
Name
Nächster Verdiensttermin
2025-02-11
Name
Neueste SEC-Einreichungen
Name
GILD's Discussions on Twitter

Vergleichen Sie GILD mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - General icon
GILD
Gilead Sciences Inc
112.77 139.85B 28.80B 6.31B 9.37B 5.02
Drug Manufacturers - General icon
LLY
Lilly Eli Co
742.91 659.07B 53.26B 13.80B -50.20M 15.30
Drug Manufacturers - General icon
JNJ
Johnson Johnson
178.76 428.83B 90.62B 22.66B 18.18B 9.35
Drug Manufacturers - General icon
ABBV
Abbvie Inc
213.00 374.37B 58.33B 3.73B 18.24B 2.10
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
128.42 245.16B 53.40B 13.68B 16.89B 6.9231
Drug Manufacturers - General icon
MRK
Merck Co Inc
84.05 213.51B 63.43B 16.42B 14.72B 6.49

Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-08-19 Hochstufung Daiwa Securities Neutral → Outperform
2025-08-08 Hochstufung Truist Hold → Buy
2025-07-25 Hochstufung Needham Hold → Buy
2025-04-22 Fortgesetzt Cantor Fitzgerald Overweight
2025-03-04 Bestätigt Oppenheimer Outperform
2025-02-18 Hochstufung Deutsche Bank Hold → Buy
2025-02-13 Hochstufung DZ Bank Hold → Buy
2025-01-10 Hochstufung Morgan Stanley Equal-Weight → Overweight
2024-12-10 Fortgesetzt BofA Securities Buy
2024-11-15 Eingeleitet Wolfe Research Outperform
2024-11-14 Eingeleitet Citigroup Buy
2024-11-08 Herabstufung Maxim Group Buy → Hold
2024-10-21 Hochstufung Leerink Partners Market Perform → Outperform
2024-10-17 Eingeleitet Bernstein Outperform
2024-10-07 Hochstufung Wells Fargo Equal Weight → Overweight
2024-07-08 Hochstufung Raymond James Mkt Perform → Outperform
2024-05-01 Bestätigt Maxim Group Buy
2024-04-24 Hochstufung HSBC Securities Reduce → Hold
2024-02-22 Herabstufung Truist Buy → Hold
2023-11-09 Eingeleitet Deutsche Bank Hold
2023-09-08 Hochstufung BofA Securities Neutral → Buy
2023-09-06 Eingeleitet HSBC Securities Reduce
2023-07-24 Bestätigt Barclays Equal Weight
2023-05-16 Hochstufung BMO Capital Markets Market Perform → Outperform
2023-04-28 Fortgesetzt Piper Sandler Overweight
2023-01-03 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2022-12-13 Fortgesetzt BofA Securities Neutral
2022-12-09 Herabstufung DZ Bank Buy → Hold
2022-10-31 Hochstufung Barclays Underweight → Equal Weight
2022-10-28 Bestätigt BMO Capital Markets Market Perform
2022-10-28 Bestätigt Cowen Outperform
2022-10-28 Bestätigt JP Morgan Overweight
2022-10-28 Bestätigt Jefferies Buy
2022-10-28 Hochstufung Piper Sandler Neutral → Overweight
2022-10-28 Bestätigt RBC Capital Mkts Outperform
2022-10-28 Hochstufung Truist Hold → Buy
2022-10-28 Bestätigt Wells Fargo Equal Weight
2022-10-04 Hochstufung JP Morgan Neutral → Overweight
2022-07-13 Eingeleitet Cantor Fitzgerald Neutral
2022-05-23 Eingeleitet SVB Leerink Mkt Perform
2022-02-28 Herabstufung BMO Capital Markets Outperform → Market Perform
2022-02-02 Bestätigt BMO Capital Markets Outperform
2022-02-02 Bestätigt BofA Securities Neutral
2022-02-02 Bestätigt RBC Capital Mkts Outperform
2022-02-02 Bestätigt Truist Hold
2022-02-02 Bestätigt Wells Fargo Equal Weight
2022-01-28 Hochstufung Argus Hold → Buy
2022-01-06 Herabstufung Morgan Stanley Overweight → Equal-Weight
2021-12-09 Fortgesetzt Wells Fargo Equal Weight
2021-12-06 Eingeleitet Goldman Neutral
2021-11-19 Hochstufung BMO Capital Markets Market Perform → Outperform
2021-11-19 Fortgesetzt Piper Sandler Neutral
2021-10-20 Fortgesetzt Cowen Outperform
2021-07-30 Bestätigt BMO Capital Markets Market Perform
2021-07-30 Bestätigt RBC Capital Mkts Outperform
2021-04-01 Hochstufung Bernstein Mkt Perform → Outperform
2021-03-30 Hochstufung Redburn Neutral → Buy
2021-01-19 Hochstufung Morgan Stanley Equal-Weight → Overweight
2021-01-04 Hochstufung Guggenheim Neutral → Buy
2020-11-03 Fortgesetzt Morgan Stanley Equal-Weight
2020-10-28 Eingeleitet UBS Neutral
2020-09-30 Fortgesetzt Jefferies Buy
2020-09-15 Hochstufung Maxim Group Hold → Buy
2020-07-31 Bestätigt Credit Suisse Neutral
2020-07-31 Bestätigt Morgan Stanley Equal-Weight
2020-07-31 Bestätigt Piper Sandler Overweight
2020-07-31 Bestätigt RBC Capital Mkts Outperform
2020-07-31 Bestätigt SunTrust Hold
2020-07-31 Bestätigt Wells Fargo Equal Weight
2020-07-20 Hochstufung Credit Suisse Underperform → Neutral
2020-06-03 Hochstufung SVB Leerink Mkt Perform → Outperform
2020-05-26 Hochstufung SunTrust Sell → Hold
2020-05-01 Herabstufung JP Morgan Overweight → Neutral
2020-05-01 Herabstufung Raymond James Outperform → Mkt Perform
2020-05-01 Herabstufung SunTrust Hold → Sell
2020-04-27 Herabstufung UBS Buy → Neutral
2020-04-20 Herabstufung BMO Capital Markets Outperform → Market Perform
2020-04-20 Herabstufung Wells Fargo Overweight → Equal Weight
2020-04-17 Herabstufung CFRA Hold → Sell
Alle ansehen

Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten

pulisher
08:31 AM

Gilead Partners With US State Department to Distribute Yeztugo to Low-Income Countries - BioSpace

08:31 AM
pulisher
07:04 AM

Rx Rundown: Novartis, Gilead Sciences, Remedy Meds and more - Medical Marketing and Media

07:04 AM
pulisher
07:01 AM

What to expect from Gilead Sciences Inc. in the next 30 daysMarket Trend Review & Low Risk Profit Maximizing Plans - Newser

07:01 AM
pulisher
05:09 AM

Gilead Sciences’ Strategic Expansion in HIV Prevention and Global Access: Assessing Long-Term Investment Potential - AInvest

05:09 AM
pulisher
05:00 AM

Gilead Sciences advances HIV prevention with new US partnership - Yahoo Finance

05:00 AM
pulisher
04:31 AM

Gilead breaks ground on AI-enabled US manufacturing hub - MarketScreener

04:31 AM
pulisher
02:50 AM

Momentum divergence signals in Gilead Sciences Inc. chartWeekly Trade Analysis & Risk Controlled Daily Trade Plans - Newser

02:50 AM
pulisher
01:48 AM

Stock Analysis | Gilead Sciences OutlookA Strong Technical Picture with Mixed Analyst Signals - AInvest

01:48 AM
pulisher
Sep 04, 2025

What earnings revisions data tells us about Gilead Sciences Inc.Trade Entry Report & Step-by-Step Swing Trade Plans - Newser

Sep 04, 2025
pulisher
Sep 04, 2025

Gilead joins U.S. efforts in expanding access to new HIV drug in low-income nations - Seeking Alpha

Sep 04, 2025
pulisher
Sep 04, 2025

US plans to bring Gilead HIV drug to market in high-burden HIV countries - Reuters

Sep 04, 2025
pulisher
Sep 04, 2025

Gilead partners with PEPFAR to expand HIV prevention access - Investing.com

Sep 04, 2025
pulisher
Sep 04, 2025

U.S. to bring Gilead’s HIV drug lenacapavir to high-burden countries - Investing.com

Sep 04, 2025
pulisher
Sep 04, 2025

Gilead Announces Partnership With PEPFAR to Deliver Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries - Business Wire

Sep 04, 2025
pulisher
Sep 04, 2025

US Plans to Bring Gilead HIV Drug to Market in High-Burden HIV Countries - U.S. News & World Report

Sep 04, 2025
pulisher
Sep 04, 2025

Gilead Sciences to Offer Lenacapavir at Cost for Global HIV Prevention - Devdiscourse

Sep 04, 2025
pulisher
Sep 04, 2025

Gilead at Wells Fargo Conference: Strategic Growth and Challenges - Investing.com

Sep 04, 2025
pulisher
Sep 04, 2025

Gilead Sciences breaks ground on new manufacturing hub - The Pharma Letter

Sep 04, 2025
pulisher
Sep 04, 2025

Australia Acute Respiratory Distress Syndrome Market Growth and Company Report 2025-2033 Featuring Silence Therapeutics, Gilead Sciences, Terumo, Getinge, Livanova, Medtronic, Fresenius, Nipro, Pfizer - GlobeNewswire

Sep 04, 2025
pulisher
Sep 04, 2025

'I can't wait to see where we go': Gilead launches $32 billion U.S. investment with new Foster City building - The Business Journals

Sep 04, 2025
pulisher
Sep 04, 2025

Gilead Breaks Ground on Pharmaceutical Development & Manufacturing Technical Development Center - Contract Pharma

Sep 04, 2025
pulisher
Sep 04, 2025

Gilead Sciences describes new Mpro inhibitors for SARS-CoV-2 - BioWorld MedTech

Sep 04, 2025
pulisher
Sep 04, 2025

Gilead begins construction of new manufacturing centre in US - World Pharmaceutical Frontiers

Sep 04, 2025
pulisher
Sep 04, 2025

Gilead Sciences Launches Choose U Campaign Spotlighting the Inspiring Experiences of People Living with HIV - Business Wire

Sep 04, 2025
pulisher
Sep 04, 2025

Gilead, Amgen kick off facility investments in US - pharmaphorum

Sep 04, 2025
pulisher
Sep 04, 2025

Gilead Sciences Launches Choose U™ Campaign Spotlighting the Inspiring Experiences of People Living with HIV - Bakersfield.com

Sep 04, 2025
pulisher
Sep 04, 2025

Gilead unveils new California manufacturing site, part of $32B US investment - FirstWord Pharma

Sep 04, 2025
pulisher
Sep 04, 2025

Gilead Sciences Breaks Ground on New Manufacturing Hub, a Cornerstone of Its U.S. Growth and Innovation Strategy - BioSpace

Sep 04, 2025
pulisher
Sep 04, 2025

Is Gilead Sciences Stock Underperforming the Nasdaq? - MSN

Sep 04, 2025
pulisher
Sep 04, 2025

Is Gilead Sciences Stock Underperforming The Nasdaq? - Barchart.com

Sep 04, 2025
pulisher
Sep 03, 2025

GILD Stock Quote Price and Forecast - CNN

Sep 03, 2025
pulisher
Sep 03, 2025

Gilead breaks ground on AI-enabled biopharma hub at Foster City headquarters - KRON4

Sep 03, 2025
pulisher
Sep 03, 2025

Gilead starts building manufacturing hub under $32 billion planned US investments - Reuters

Sep 03, 2025
pulisher
Sep 03, 2025

Gilead Sciences’ Strategic Position in the Evolving Biopharma Landscape - AInvest

Sep 03, 2025
pulisher
Sep 03, 2025

Gilead breaks ground on Foster City manufacturing hub as $32B US investment plan plays out - Fierce Pharma

Sep 03, 2025
pulisher
Sep 03, 2025

Gilead at Cantor Global Healthcare Conference: Strategic Focus on Innovation - Investing.com

Sep 03, 2025
pulisher
Sep 03, 2025

Gilead Sciences' $32 Billion U.S. Expansion and Its Implications for Biopharma Innovation and Stock Value - AInvest

Sep 03, 2025
pulisher
Sep 03, 2025

Gilead Sciences $32B Investment in US Pharma ManufacturingNews and Statistics - IndexBox

Sep 03, 2025
pulisher
Sep 03, 2025

Gilead Sciences’ $32 Billion U.S. Expansion and Its Implications for Biopharma Leadership - AInvest

Sep 03, 2025
pulisher
Sep 03, 2025

4 Questions on Gilead’s New Technical Development Center with Stacey Ma & Jamie Moore - Gilead Sciences

Sep 03, 2025
pulisher
Sep 03, 2025

Gilead Sciences Breaks Ground on New Manufacturing Center at California HQ - MarketScreener

Sep 03, 2025
pulisher
Sep 03, 2025

Gilead's $32 Billion US Manufacturing Expansion: A Strategic Catalyst for Long-Term Shareholder Value - AInvest

Sep 03, 2025
pulisher
Sep 03, 2025

Gilead breaks ground on manufacturing development site at California HQ - Seeking Alpha

Sep 03, 2025
pulisher
Sep 03, 2025

Gilead breaks ground on new Bay Area facility as part of $32 billion investment By Investing.com - Investing.com

Sep 03, 2025
pulisher
Sep 03, 2025

Gilead Sciences' $32 Billion U.S. Investment: A Strategic Catalyst for Biopharma Innovation and Shareholder Value - AInvest

Sep 03, 2025
pulisher
Sep 03, 2025

Gilead Sciences breaks ground on new manufacturing facility in Foster City - StreetInsider

Sep 03, 2025
pulisher
Sep 03, 2025

Intraday pattern recognizer results for Gilead Sciences Inc.Market Risk Analysis & Growth Focused Entry Reports - Newser

Sep 03, 2025
pulisher
Sep 03, 2025

Will Gilead Sciences Inc. stock go up soon2025 Dividend Review & Community Consensus Trade Alerts - Newser

Sep 03, 2025
pulisher
Sep 03, 2025

How hedge fund analytics apply to Gilead Sciences Inc. stockTake Profit & Growth Oriented Trade Recommendations - Newser

Sep 03, 2025
pulisher
Sep 03, 2025

Using RSI to spot recovery in Gilead Sciences Inc.2025 Retail Activity & High Return Stock Watch Alerts - Newser

Sep 03, 2025
pulisher
Sep 02, 2025

Gilead's $0.5B Volume Ranks 215th as Q2 Sales Climb and Yeztugo Approval Signals Long-Term Innovation - AInvest

Sep 02, 2025

Finanzdaten der Gilead Sciences Inc-Aktie (GILD)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
drug_manufacturers_general PFE
$24.54
price down icon 1.01%
$280.10
price down icon 1.32%
drug_manufacturers_general SNY
$45.33
price down icon 9.14%
drug_manufacturers_general NVO
$56.14
price down icon 1.06%
drug_manufacturers_general MRK
$84.05
price down icon 0.15%
Kapitalisierung:     |  Volumen (24h):